|
|
Navidea Biopharmaceuticals, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: Gottlieb: FDA pursuing faster approval path for diagnosticsThanks oxy and Fall. By suppostion, Navidea is now seeking a general use (my words) designation from FDA for use of tilManocept in macrophage I/D. Unclear if that designation is part of R/A P3 or separate, so that general designation must already be obtainable for in vivo I/D. |
||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 27251 | Re: Gottlieb: FDA pursuing faster approval path for diagnostics | dwdinvesting | 0 | 9/21/2018 2:27:04 PM |
